Regulations covering public health should override personal rights and the country cannot wait any more for a good public health law. The health care industry, including institutions of medical education, hospitals and pharmaceutical businesses, have grown into behemoths that can do considerable harm in the absence of independent and effective regulatory systems. While there are no success stories in the regulation of any kind of industry in India, I will focus...
More »SEARCH RESULT
Meet PM’s change agents-Amit Gupta
Twenty-two newbie managers, fresh from B-schools across India, are raring to go. Only, they won’t make spreadsheets to sell soaps or fizzy drinks. From June, they will assist senior bureaucrats across 11 districts of Jharkhand where the Centre is funding uplift schemes. These managers — from IIT-Kharagpur, Tata Institute of Social Sciences (TISS)-Mumbai, Visva-Bharti in Bengal’s Santiniketan, XISS-Ranchi, XLRI-Jamshedpur and others — are Prime Minister’s Rural Development Fellows in some of...
More »Gates cash for AIDS fight to stop in 2013
-The Telegraph The decade-long flow of funds from the Bill and Melinda Gates Foundation into India’s HIV control efforts will stop from June 2013, a foundation official said today, intensifying fears among sections of health activists about the future of the programme. Avahan was the first large-scale health initiative in India to be supported by the foundation, said to be t he world’s largest philanthropic organisation, and will be the first to...
More »Bayer to challenge Cipla’s decision to cut price of cancer drug
-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...
More »Patent to plunder -Amit Sengupta
India's efforts to produce and supply life-saving drugs at affordable prices face challenges from multinational companies trying to “evergreen” their patents. THE average life expectancy across the globe has increased from around 30 years a century ago to over 65 years today. This has been made possible in large part by modern medicine. Never before in history have humans had access to such an array of medicines and devices to...
More »